Mechanistically, ASB16-AS1 activates the NF-κB pathway via inducing TRIM37 phosphorylation to facilitate tumor growth, stemness, and cisplatin (CDDP) resistance in GC (Fu et al., 2021). Here, TRIM37 is linked to gastric cancer.